[Glucose lowering drugs in case of impaired renal function].
Marijke A J Assink, Alferso C Abrahams, Maarten B. Rookmaaker
Abstract
Marijke A J Assink, Alferso C Abrahams, Maarten B. Rookmaaker
Abstract
Evidence-based guidelines describe the optimal implementation order of different classes of anti-diabetic drugs in patients with type 2 diabetes mellitus (DM2). Renal impairment affects 20-40% of the DM2 patients. Guidelines do not provide information about the applicability of individual anti-diabetic drugs in patients with DM2 and impaired renal function. Renal impairment not only affects the pharmacokinetics of anti-diabetic drugs but glucose metabolism as well. Pharmacokinetic properties, as well as clinical experience with individual anti-diabetic drugs, should be used to evaluate the applicability of anti-diabetic drugs. In patients with DM2 and a creatinine clearance ≥ 60 ml/min/1.73 m2 all anti-diabetic drugs can be used at standard doses. In patients with DM2 and a creatinine clearance < 60 ml/min/1.73 m2 certain anti-diabetic drugs are contraindicated, while others should be dose-adjusted. A limited number of anti-diabetic drugs can be dosed independent of renal function.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Evidence-based guidelines describe the optimal implementation order of different classes of anti-diabetic drugs in patients with type 2 diabetes mellitus (DM2). Renal impairment affects 20-40% of the DM2 patients. Guidelines do not provide information about the applicability of individual anti-diabetic drugs in patients with DM2 and impaired renal function. Renal impairment not only affects the pharmacokinetics of anti-diabetic drugs but glucose metabolism as well. Pharmacokinetic properties, as well as clinical experience with individual anti-diabetic drugs, should be used to evaluate the applicability of anti-diabetic drugs. In patients with DM2 and a creatinine clearance ≥ 60 ml/min/1.73 m2 all anti-diabetic drugs can be used at standard doses. In patients with DM2 and a creatinine clearance < 60 ml/min/1.73 m2 certain anti-diabetic drugs are contraindicated, while others should be dose-adjusted. A limited number of anti-diabetic drugs can be dosed independent of renal function.
Key concepts: Medicine, Renal function, Pharmacokinetics, Impaired renal function, Diabetes mellitus, Creatinine, Pharmacology, Urology